Managing Adverse Effects of Incretin-Based Medications for Obesity
JAMA · 02.09.2025 · 334 (9) · 822
DOI: 10.1001/jama.2025.11153 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 02.09.2025. Verfasst von Robert F Kushner und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine and Medical Education, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
This JAMA Insights explores optimal strategies for managing the adverse effects associated with incretin-based medications for obesity, including semaglutide and tirzepatide.
Autor:innen und Institutionen
- Departments of Medicine and Medical Education, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
- Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas.
- Washington Center for Weight Management and Research, Washington, DC.
Zitieren
APA
Kushner, R. F., Almandoz, J. P., & Rubino, D. M. (2025). Managing Adverse Effects of Incretin-Based Medications for Obesity. JAMA, 334(9), 822. https://doi.org/10.1001/jama.2025.11153
Vancouver
Kushner RF, Almandoz JP, Rubino DM. Managing Adverse Effects of Incretin-Based Medications for Obesity. JAMA. 2025;334(9):822. doi:10.1001/jama.2025.11153
BibTeX
@article{Kushner2025,
author = {Kushner, Robert F and Almandoz, Jaime P and Rubino, Domenica M},
title = {Managing Adverse Effects of Incretin-Based Medications for Obesity},
journal = {JAMA},
year = {2025},
volume = {334},
number = {9},
pages = {822},
doi = {10.1001/jama.2025.11153}
}
EUVIMED